Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Fall on the Road
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Northwest Christmas
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Chimerix Inc
(NQ:
CMRX
)
0.9700
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 6, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Chimerix Inc
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
December 04, 2023
Proven Leader Brings More Than 25 Years of Financial Experience
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 24, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
November 16, 2023
Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
November 02, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
October 26, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Participate in Upcoming Investor Conferences
September 05, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
August 16, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
August 03, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
July 27, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer
June 27, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 31, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House
May 25, 2023
Forum Aim is to Share Progress and Spur Actions to Advance the Field
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update
May 04, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023
April 27, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting
April 18, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update
March 02, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference
February 28, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023
February 23, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update
December 08, 2022
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Responds to Rubric Capital Management
November 10, 2022
Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans
From
Chimerix, Inc.
Via
GlobeNewswire
Rubric Capital Management Sends Letter to Chimerix Board of Directors
November 10, 2022
From
Rubric Capital Management LP
Via
Business Wire
Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update
November 03, 2022
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022
October 27, 2022
From
Chimerix, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.